Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1446-1456

  Yao, X ^a   Anderson, D L ^a   Ross, S A ^a   Lang, D G ^a   Desai, B Z ^a   Cooper, D C ^a   Wheelan, P ^a   McIntyre, M S ^a   Bergquist, M L ^a   MacKenzie, K I ^a,b   Becherer, J D ^a   Hashim, M A ^a  

^a GLAXOSMITHKLINE   (United States)

^b Bioanalytics   (Australia)

Author keywords

Drug development; Drug induced QT prolongation; hERG potassium channel; Patch clamping; Surface ECG (electrocardiogram); TdP (torsade de pointes)

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN; CAPTOPRIL; CISAPRIDE; DROPERIDOL; HALOPERIDOL; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; PROPRANOLOL; QUINIDINE; SOTALOL; SPARFLOXACIN; TAMOXIFEN; TERFENADINE; VERAPAMIL; ZIPRASIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; GUINEA PIG; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PATCH CLAMP; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION;

ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HUMANS; LONG QT SYNDROME; MASS SPECTROMETRY; MODELS, ANIMAL; PATCH-CLAMP TECHNIQUES; PHARMACEUTICAL PREPARATIONS;

EID: 48149096544     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.267     Document Type: Article

References (46)

1. Antzelevitch C (2001). Tpeak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 31: 555-557.
2. Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD et al. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 49: 27S-33S.
3. Bass AS, Tomaselli G, Bullingham III R, Kinter LB (2005). Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. J Pharmacol Toxicol Methods 52: 12-21.
4. Busch AE, Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J (1994). The novel class III antiarrhythmics NE-10064 and NE10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. Biochem Biophys Res Commun 202: 265-270.
5. Carlsson L (2001). Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J (Supplement K) 3: K114-K120.
6. Cavero I (2008). Safety Pharmacology Society: 7th annual meeting 19-20 September. Expert Opin Drug Safety 7: 91-100.
7. Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY et al. (2005). Prediction of the risk of torsade de pointes using the model of isolated canine Purkinje fibres. Br J Pharmacol 144: 376-385.
8. Committee for Proprietary Medicinal Products (1997). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP document number: CPMP/986/96. European Agency for the Evaluation of Medicinal Products: London.
9. Crumb W, Cavero I (1999). QT interval prologation by noncardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 2: 270-280.
10. + channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292: 261-264.
11. Darpo B (2001). Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J (Supplement K) 3: K70-K80.
12. De Bruin ML, Pettersson LM, Meyboom RHB, Hoes AW, Leufkens HGM (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-597.
13. Editorial Supervision by Pharmaceutical and Cosmetics Division, Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1995). Japanese Guidelines for Nonclinical Studies of Drugs Manual: Yakuji Nippo Ltd., Tokyo.
14. Farhangi V, Sansone RA (2003). QTc prolongation due to propranolol overdose. Int J Psychiatry Med 33: 201-202.
15. Fermini B, Fossa AA (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439-447.
16. Fischler M, Bonnet F, Trang H, Jacob L, Levron JC, Flaisler B et al. (1986). The pharmacokinetics of droperidol in anesthetized patients. Anesthesiology 64: 486-489.
17. Fossa AA, Wisialowski T, Wolfgang E, Wang E, Avery M, Raunig DL et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternant in the guinea pig. Eur J Pharmacol 486: 209-221.
18. Gerhardy A, Scholtysik G, Schaad A, Haltiner R, Hess T (1998). Generating and influencing torsades de pointes - like polymorphic ventricular tachycardia in isolated guinea pig hearts. Basic Res Cardiol 93: 285-294.
19. González MA, Estes KS (1998). Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 36: 292-300.
20. Gras J, Llenas J (1999). Effects of H1 antihistamines on animal models of QTc prolongation. Drug Safety 21: 39-44.
21. Hamlin RL, Kijtawornrat A, Keene BW, Hamlin DM (2003). QT and RR intervals in conscious and anaesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol Sci 76: 437-442.
22. Hammond TG, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Redfern WS et al. (2001). Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 49: 741-750.
23. Hardman JG, Limbird LE (2006a). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 1927-2020.
24. Hardman JG, Limbird LE (2006b). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 955.
25. Hardman JG, Limbird LE (2006c). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 700.
26. Hauser DS, Stade M, Schmidt A, Hanauer G (2005). Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model. J Pharmacol Toxicol Methods 52: 106-114.
27. Hondeghem LM, Hoffmann P (2003). Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependency and instability. J Cardiovasc Pharmacol 41: 14-24.
28. Kii Y, Nakatsuji K, Nose I, Yabuuchi M, Mizuki Y, Ito T (2001). Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol Toxicol 89: 96-103.
29. Kirsch GI, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochlan MC et al. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50: 93-101.
30. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3: 948-956.
31. 2+ overload with R56865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. Eur J Pharmacol 235: 89-93.
32. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M et al. (1988). Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 16: 403-409.
33. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A (2000). The effects of ketoconazole on ziprasidone pharmacokinetics - a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol 49: 71S-76S.
34. Minematsu T, Ohtani H, Sato H, Iga T (1999). Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci 65: PL197-PL202.
35. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790.
36. Morganroth J, Talbot GH, Dorr MB, Johnson RD, Geary W, Magner D (1999). Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Ther 21: 818-828.
37. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
38. Salama G, London B (2007). Mouse models of long QT syndrome. J Physiol 578: 43-53.
39. Shah RR, Hondeghem LM(2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-772.
40. Shimada J, Nogita T, Ishibashi Y (1993). Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 25: 358-369.
41. Song JC, White CM (2002). Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors. Clin Pharmacokinet 41: 207-224.
42. Sosunov EA, Anyukhovsky P, Rosen MR (1996). Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. J Pharmacol Exp Thera 278: 906-912.
43. Tashibu H, Miyazaki H, Aoki K, Akie Y, Yamamoto K (2005). QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J Pharm Sci 99: 473-486.
44. Testai L, Calderone V, Salvadori A, Breschi MC, Nieri P, Martinotti E (2004). QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J Appl Toxicol 24: 217-222.
45. Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsade de pointes. Curr Opin Drug Discov Dev 5: 116-126.
46. Yao X, McIntyre MS, Lang DG, Song IH, Becherer JD, Hashim MA (2005). Propranolol inhibits the human ether-a-go-go-related gene potassium channels. Eur J Pharmacol 519: 208-211.